In the News

Aptinyx Restarts Study of Treatment for Cognitive Impairment in PD and DLB

Aptinyx Restarts Study of Treatment for Cognitive Impairment in PD and DLB

Aptinyx, Inc. was forced to suspend its study of NYX-458—a treatment for cognitive impairment in Parkinson’s disease (PD) and dementia with Lewy bodies (DLB)—due to the COVID-19 pandemic. Last week the biopharmaceutical company announced that they’ll again start screening patients for their Phase 2 study.

The protein alpha-synuclein, which causes PD and DLB, has been shown to reduce the activity of NMDA, a receptor that plays an important role in memory and learning. NYX-458 may be able to protect NMDA from the effects of alpha-synuclein. It’s already been shown to reverse cognitive decline in non-human primates.

Aptinyx will study the safety, tolerability, and potential cognitive benefits of NYX-458 versus placebo in a 12-week study of 100 patients. Data from the Phase 2 trial are expected to be released in the second half of 2022.

READ MORE
CND Life Sciences

CND Life Sciences

CND Life Sciences is the creator of the Syn-One Test™, the world’s first commercially available test to visualize abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test is an objective, evidence-based diagnostic tool to aid in the diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or REM sleep behavior disorder.